Cycle Group to Acquire Applied Therapeutics in Private Deal

Acquisition Details: Applied Therapeutics Inc. has agreed to be acquired by Cycle Group Holdings Ltd., with a tender offer of $0.088 per share in cash and additional contingent value rights tied to future regulatory milestones for their lead candidate, Govorestat.

Govorestat's Potential: Govorestat is being developed for treating rare CNS metabolic diseases, including Classic Galactosemia and CMT-SORD, with potential cash payouts for shareholders upon FDA approvals and sales milestones.

Financial Support: Applied Therapeutics has issued an $8.5 million unsecured promissory note to Cycle to support operations until the acquisition closes, as they indicated they could not continue operations without this funding.

Market Performance: APLT's stock has seen significant declines, trading between $0.20 and $1.50, closing at $0.21 before dropping to $0.14 in overnight trading, reflecting a 34.53% decrease.